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Letters to the Editor 
Dear Editor 
Amiodarone pneumonitis: no safe dose 
Polkey et al. (1) state that pulmonary toxicity with 
amiodarone is unusual at a maintenance dose below 
200mg day-‘. The following case report suggests 
that vigilance is required despite ‘low-dose amio- 
darone’ treatment. 
A 65year-old man presented with a 2-month 
history of progressive dyspnoea and dry cough. He 
had a history of paroxysmal atria1 fibrillation and 
had been commenced on amiodarone 18 months 
before. A loading dose of 600 mg daily for 7 days was 
followed by a maintenance dose of 100 mg daily. 
There was no history of myocardial infarction, heart 
failure, relevant occupational history nor exposure to 
avian antigen. On examination he was apyrexial. He 
was not clubbed and there was no lymphadenopathy. 
There were sparse inspiratory crackles at both bases. 
Routine haematology and biochemistry were un- 
remarkable and additional laboratory investigations 
were unhelpful. Serum amiodarone level was 0,2 mg 
1 - ’ (range 062.5) and desethylamiodarone level 
was 0.3 mg 1 - i (range 0.625). Lung function values 
were consistent with a severe restrictive defect, and a 
chest radiograph showed widespread alveolar and 
interstitial shadowing. An open lung biopsy showed 
diffuse interstitial pulmonary fibrosis involving both 
alveolar and interlobar septa. In several areas there 
were foci of fibrous and granulation tissue within the 
alveolar ducts and alveoli consistent with amiodarone- 
induced pulmonary toxicity. Amiodarone was with- 
drawn with improvement in radiological appearances 
and lung function and a return to normal values within 
6 months. 
Physicians should be aware that a life-threatening 
pneumonitis may occur even with doses below 
200mg day-‘. Every effort should be made to 
establish the lowest effective dose of amiodarone 
consistent with symptom and rhythm control. 
M. R. HARGREAVES AND M. K. BENSON 
Oxford RadclifSe Hospital NHS Trust 
Oxford, U.K. 
2 April 1995 
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Reply to Dr Hargreaves and Dr Benson 
I thank Dr Hargreaves and Dr Benson for their 
interest in our case. Their case is in many respects 
similar, as is the case recently described by Valle et al. 
(1). However, surely the lesson of these cases is not to 
use amiodarone in the lowest dose consistent with 
symptom and rhythm control which is, in any case, 
just good medical practice. Rather the question 
raised by these cases is whether greater emphasis 
should be placed on screening- for example, by 
spirometry or gas transfer measurements - users of 
low dose amiodarone. 
M. POLKEY 
King’s College School of Medicine & Dentistry 
London, U. K 
6 July 1995 
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Dear Editor 
Death in notified cases of tuberculosis in Edinburgh: 
1983-1992 
We read with interest the recent survey by Selby 
et al. (1) of the mortality from tuberculosis in 
Edinburgh. Their findings are in agreement with a 
similar study reported recently from Leeds (2). 
In a retrospective study, we reviewed all notifi- 
cations in the city (population 730 000) with tubercu- 
losis in the 5-yr period 19861990. The mortality data 
are summarized in Table 1. Of 375 confirmed notifi- 
cations, 53 (14%) patients died. Thirty-nine (10%) of 
these patients died from tuberculosis, with 26/37 
(67%) of deaths diagnosed at post mortem. Death 
from tuberculosis and diagnosis at post mortem was 
much more frequent in older subjects. Thirty-one 
(28%) subjects aged 65 years and older died from 
tuberculosis, compared with eight (3%) younger sub- 
jects (P<O.OOl by Chi-squared testing). Twenty-three 
(21%) elderly patients compared with three (1%) 
younger adults were diagnosed at post mortem 
(P<O.OOl by Chi-squared testing). 
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